Fight against COVID-19
Diagnostic antibody & antigen
Services
- Custom AAV Production
- Custom Adenovirus Production
- Custom Lentivirus Production
- Pre-made AAV Production
- Pre-made Adenovirus Production
- Pre-made Lentivirus Production
- AAV-LC3 Autophagy Flux Detection
- Ad-LC3 Autophagy Flux Detection
- Lv-LC3 Autophagy Flux Detection
- AAV Control Virus Production
- CRISPR/Cas9 AAV Production
- CRISPR/Cas9 Adenovirus Production
Supports
SOCAIL MEDIA
Pre-made Monalizumab benchmark antibody ( Whole mAb, anti-KLRC1/NKG2A therapeutic antibody, Anti-CD159A/NKG2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-355
Pre-Made Monalizumab biosimilar, Whole mAb, Anti-KLRC1/NKG2A Antibody: Anti-CD159A/NKG2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-355-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-355-10mg | 10mg | 21890 | ||
| GMP-Bios-ab-355-100mg | 100mg | 148000 | ||
| GMP-Bios-ab-355-xmg | ＞100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Monalizumab biosimilar, Whole mAb, Anti-KLRC1/NKG2A Antibody: Anti-CD159A/NKG2 therapeutic antibody |
| INN Name | Monalizumab |
| Target | NKG2A |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk |
| Conditions Approved | na |
| Conditions Active | Head and neck cancer;Non-small cell lung cancer;Cervical cancer;Chronic lymphocytic leukaemia;Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours;Haematological malignancies |
| Conditions Discontinued | Inflammation;Rheumatoid arthritis |
| Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
